Scarica l'app Stockscreener
8.4885
4.74%
-0.3815
Precedente Chiudi:
$8.87
Aprire:
$8.45
Volume 24 ore:
5,336
Relative Volume:
0.03
Capitalizzazione di mercato:
$158.97M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+37.99%
1M Prestazione:
+55.68%
6M Prestazione:
+221.97%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$8.44
$8.50
Intervallo di 1 settimana:
$6.17
$8.95
Portata 52W:
$2.14
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
Nome
Kalaris Therapeutics Inc
Settore
Industria
Telefono
650-249-2727
Indirizzo
400 CONNELL DRIVE, BERKELEY HEIGHTS
Confronta KLRS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
8.50 | 165.89M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.04 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.52 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
856.05 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.28 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
195.56 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-03 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-07-23 | Ripresa | Piper Sandler | Neutral |
| 2025-05-07 | Iniziato | Leerink Partners | Outperform |
| 2025-04-08 | Iniziato | William Blair | Outperform |
Kalaris Therapeutics Inc Borsa (KLRS) Ultime notizie
Kalaris Therapeutics Inc. $KLRS Shares Sold by Gilead Sciences Inc. - MarketBeat
Is Kalaris Therapeutics Inc. stock a good choice for value investorsEarnings Beat & Verified High Yield Trade Plans - Newser
Kalaris Therapeutics (KLRS) Stock Analysis Report | Financials & Insights - Benzinga
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives $11.50 Consensus Target Price from Brokerages - Defense World
Kalaris Therapeutics Inc Stock Analysis and ForecastGeopolitical Risk Analysis & Plan Your Future With Strategic Investing - earlytimes.in
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
We Think Kalaris Therapeutics (NASDAQ:KLRS) Needs To Drive Business Growth Carefully - Yahoo Finance
What analysts say about Kalaris Therapeutics Inc stockCandlestick Pattern Analysis & Rapid Capital Growth - earlytimes.in
Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference - The Globe and Mail
Kalaris (Nasdaq: KLRS) to present at Noble Capital 21st Emerging Growth Conference - Stock Titan
Kalaris Therapeutics, Inc. (KLRS) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Kalaris Therapeutics Inc. (KLRS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What risks investors should watch in Kalaris Therapeutics Inc. stockJuly 2025 Short Interest & Short-Term High Return Strategies - newser.com
Equities Analysts Offer Predictions for KLRS Q4 Earnings - Defense World
Leerink Partnrs Issues Pessimistic Outlook for KLRS Earnings - MarketBeat
Kalaris Therapeutics (NASDAQ:KLRS) Is In A Good Position To Deliver On Growth Plans - Sahm
What’s next for Kalaris Therapeutics Inc. stock priceTrade Exit Summary & Trade Opportunity Analysis - newser.com
Will Kalaris Therapeutics Inc. stock benefit from commodity pricesLong Setup & Daily Volume Surge Trade Alerts - newser.com
What MACD and RSI say about Kalaris Therapeutics Inc.2025 Trading Recap & Risk Controlled Stock Alerts - newser.com
Can Kalaris Therapeutics Inc. stock deliver surprise earnings beat - newser.com
Can Kalaris Therapeutics Inc. rally from current levelsMarket Growth Summary & Stepwise Trade Execution Plans - newser.com
Kalaris stock rating reiterated at Strong Buy by Raymond James - Investing.com Canada
Kalaris Therapeutics Reports Q3 2025 Financial Progress - MSN
How to use a screener to detect Kalaris Therapeutics Inc. breakoutsWeekly Investment Report & Verified Momentum Watchlists - newser.com
Kalaris Therapeutics (KLRS) Price Target Increased by 10.87% to 17.34 - Nasdaq
Analyzing Kalaris Therapeutics Inc. with risk reward ratio charts2025 Support & Resistance & Growth Focused Stock Pick Reports - newser.com
Applying sector rotation models to Kalaris Therapeutics Inc.Oil Prices & Technical Confirmation Trade Alerts - newser.com
What to expect from Kalaris Therapeutics Inc. in the next 30 daysMarket Performance Summary & Consistent Profit Trading Strategies - newser.com
Does Kalaris Therapeutics Inc. qualify in momentum factor screeningMarket Rally & AI Driven Price Predictions - newser.com
What is William Blair's Estimate for KLRS FY2025 Earnings? - MarketBeat
William Blair Has Negative Estimate for KLRS FY2025 Earnings - Defense World
Kalaris Therapeutics Inc Azioni (KLRS) Dati Finanziari
Non sono disponibili dati finanziari per Kalaris Therapeutics Inc (KLRS). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.42%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):